Greg Parekh, Phd

Biography

Nayan Gregory Parekh, PhD, Chairman of the Board, is a founding partner at New Rhein Healthcare Investors LLC/BVBA. He serves as Chairman of the Board of Softhale Sprl, a respiratory drug device platform company; is a board member of CancerLinQ LLC, focused on big data and health informatics; and is a senior advisor to the American Society of Clinical Oncology (ASCO). From 2011 to 2013, Dr. Parekh was Chief Executive Officer of Biocartis SA focused on oncology molecular diagnostics. Previously, Dr. Parekh was the worldwide head of M&A at Novartis, where he was the chief integration manager for the Alcon/Novartis merger and a member of the Novartis Group Finance Committee. At Novartis, Dr. Parekh led the execution of over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, he spent 10 years in pharmaceuticals and biotechnology investment banking including Managing Director and Head of the European Healthcare Group for Deutsche Bank AG based in London and Vice President in the Therapeutics Group for JP Morgan in New York. He holds a PhD in Economics from Northwestern University. 

Research Interest

Chase Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease. The company’s development programs have the potential to profoundly improve the symptomatic treatment of Alzheimer's disease.